- Home
- VOR vs LXEO Comparison
VOR vs LXEO Comparison
Compare VOR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- LXEO
- Stock Information
- Founded
- VOR 2015
- LXEO 2017
- Country
- VOR United States
- LXEO United States
- Employees
- VOR N/A
- LXEO N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- LXEO
- Sector
- VOR Health Care
- LXEO
- Exchange
- VOR Nasdaq
- LXEO Nasdaq
- Market Cap
- VOR 261.0M
- LXEO 279.7M
- IPO Year
- VOR 2021
- LXEO 2023
- Fundamental
- Price
- VOR $1.57
- LXEO $5.21
- Analyst Decision
- VOR Buy
- LXEO Strong Buy
- Analyst Count
- VOR 6
- LXEO 7
- Target Price
- VOR $3.90
- LXEO $15.29
- AVG Volume (30 Days)
- VOR 4.4M
- LXEO 426.8K
- Earning Date
- VOR 11-06-2025
- LXEO 11-12-2025
- Dividend Yield
- VOR N/A
- LXEO N/A
- EPS Growth
- VOR N/A
- LXEO N/A
- EPS
- VOR N/A
- LXEO N/A
- Revenue
- VOR N/A
- LXEO N/A
- Revenue This Year
- VOR N/A
- LXEO N/A
- Revenue Next Year
- VOR N/A
- LXEO N/A
- P/E Ratio
- VOR N/A
- LXEO N/A
- Revenue Growth
- VOR N/A
- LXEO N/A
- 52 Week Low
- VOR $0.13
- LXEO $1.45
- 52 Week High
- VOR $3.29
- LXEO $11.72
- Technical
- Relative Strength Index (RSI)
- VOR 33.31
- LXEO 60.70
- Support Level
- VOR $1.80
- LXEO $4.90
- Resistance Level
- VOR $2.03
- LXEO $5.56
- Average True Range (ATR)
- VOR 0.13
- LXEO 0.29
- MACD
- VOR -0.05
- LXEO 0.02
- Stochastic Oscillator
- VOR 10.30
- LXEO 61.96
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.